The collaboration integrates serial tumor-informed ctDNA testing into Aveta’s global registrational Phase 3 program.
New Phase 2A analyses examine HPV16, NF-κB signaling and immune activation following APG-157 treatment.
The global AVTA-30-01 study design will be presented to the head and neck oncology community.
Spatial profiling data describe APG-157-induced remodeling of the tumor immune microenvironment.
Phase 2A results evaluate neoadjuvant APG-157 monotherapy in locally advanced head and neck cancer.
The designation supports expedited development and review of APG-157 in this serious disease.
Experienced biopharmaceutical leader joins Aveta as the company advances APG-157.
MEDIA INQUIRIES